Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670707 · ClinicalTrials.gov registry record · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
A Phase 3 study of Langerhans Cell Histiocytosis, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
- 11
- Study locations
NCT02670707 is a Phase 3 study of Langerhans Cell Histiocytosis that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 124 participants, below the 1,124-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (89% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT02670707, a Phase 3 study of Langerhans Cell Histiocytosis, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
- 11
- Study locations
Study Summary
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions. For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH. The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.
Conditions Studied
Interventions
- DRUG Cytarabine
- DRUG Vinblastine/prednisone
Study Locations (11)
Texas
- Dell Children's Medical Center - Austin
- Cook Children's Health Care System - Fort Worth
- Texas Children's Hospital - Houston
- Vannie Cook Children's Clinic - McAllen
- Children's Hospital of San Antonio - San Antonio
California
- Stanford Children's Hospital, Lucile Packard Children's Hospital - Palo Alto
- Rady Children's Hospital - San Diego - San Diego
Minnesota
- University of Minnesota/Masonic Cancer Center - Minneapolis
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Lehigh Valley Health Network- Cedar Crest - Allentown
Virginia
- Children's Hospital of The King's Daughters - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2016-03-07 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670707
The ClinicalTrials.gov registry entry for NCT02670707 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,124-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (89% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 2 interventions - of which Cytarabine is the first listed.
NCT02670707 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02670707 about?
NCT02670707 is a clinical study titled "Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)". Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (change...
What is the current status of trial NCT02670707?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2016-03-07. Estimated completion is 2029-01.
What conditions does trial NCT02670707 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT02670707?
The interventions under investigation include: Cytarabine (DRUG), Vinblastine/prednisone (DRUG).
Who is sponsoring clinical trial NCT02670707?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02670707 being conducted?
This trial has 11 study locations across California, Minnesota, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Histiocytic Disorder Follow-up Study
RECRUITING
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.